101,876 Zoetis Inc. $ZTS Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 918,176 shares of the company’s stock after selling 101,876 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.22% of Zoetis worth $64,116,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zoetis in the 3rd quarter valued at about $8,169,000. Profund Advisors LLC raised its position in Zoetis by 226.7% during the third quarter. Profund Advisors LLC now owns 25,433 shares of the company’s stock valued at $1,776,000 after purchasing an additional 17,649 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Zoetis by 5.6% in the 3rd quarter. ProShare Advisors LLC now owns 115,215 shares of the company’s stock valued at $8,045,000 after purchasing an additional 6,119 shares in the last quarter. Vise Technologies Inc. increased its holdings in Zoetis by 52.9% in the 3rd quarter. Vise Technologies Inc. now owns 14,886 shares of the company’s stock worth $1,039,000 after purchasing an additional 5,151 shares in the last quarter. Finally, Cidel Asset Management Inc. lifted its holdings in shares of Zoetis by 17.5% during the third quarter. Cidel Asset Management Inc. now owns 4,003 shares of the company’s stock worth $280,000 after purchasing an additional 595 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ZTS shares. BNP Paribas Exane lowered their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Piper Sandler reduced their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. BTIG Research dropped coverage on Zoetis in a research report on Friday, October 30th. They set a “buy” rating for the company. Stifel Nicolaus decreased their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. Finally, Citigroup lowered their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $93.79.

Zoetis Trading Up 0.0%

Shares of ZTS opened at $83.19 on Wednesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market cap of $34.38 billion, a P/E ratio of 13.71, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49. The company has a 50 day simple moving average of $75.27 and a two-hundred day simple moving average of $93.22.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.5%. Zoetis’s payout ratio is currently 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.